FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1521800058> ?p ?o ?g. }

• W1521800058 endingPage "12290" @default.
• W1521800058 startingPage "12273" @default.
• W1521800058 abstract "// Tsai-Hsien Hung 1 , Sheng-Chi Hsu 4,5 , Ching-Yi Cheng 6 , Kong-Bung Choo 7 , Ching-Ping Tseng 1,2,3 , Tse-Ching Chen 4,5 , Ying-Wei Lan 1 , Tsung-Teng Huang 8 , Hsin-Chih Lai 1,2 , Chuan-Mu Chen 9,10,11 and Kowit-Yu Chong 1,2,3 1 Graduate Institute of Biomedical Sciences, Division of Biotechnology, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan, Republic of China 2 Department of Medical Biotechnology and Laboratory Science, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan, Republic of China 3 Molecular Medicine Research Center, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan, Republic of China 4 Cancer Molecular Diagnostic Laboratory, Chang Gung Memorial Hospital, Lin-Kou Medical Center, Tao-Yuan, Taiwan, Republic of China 5 Department of Pathology, Chang Gung Memorial Hospital, Lin-Kou Medical Center, Tao-Yuan, Taiwan, Republic of China 6 Department of Cosmetic Science, Graduate Institute of Health Industry Technology, Research Center for Industry of Human Ecology, Chang Gung University of Science and Technology, Tao-Yuan, Taiwan, Republic of China 7 Department of Preclinical Sciences, Faculty of Medicine and Health Sciences and Centre for Stem Cell Research, Universiti Tunku Abdul Rahman, Selangor, Malaysia 8 Center for Molecular and Clinical Immunology, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan, Republic of China 9 Department of Life Sciences, National Chung Hsing University, Taichung, Taiwan, Republic of China 10 Agricultural Biotechnology Center, National Chung Hsing University, Taichung, Taiwan, Republic of China 11 Rong-Hsing Translational Medicine Center, National Chung Hsing University, Taichung, Taiwan, Republic of China Correspondence: Kowit Yu Chong, email: // Keywords : Multiple Drug Resistance, Wnt5A, shRNA, Cell cycle, apoptosis Received : June 17, 2014 Accepted : October 23, 2014 Published : October 24, 2014 Abstract Multidrug resistance in cancer cells arises from altered drug permeability of the cell. We previously reported activation of the Wnt pathway in ABCB1-overexpressed human uterus sarcoma drug-resistant MES-SA/Dx5 cells through active β-catenin and associated transactivation activities, and upregulation of Wnt-targeting genes. In this study, Wnt5A was found to be significantly upregulated in MES-SA/Dx5 and MCF7/ADR2 cells, suggesting an important role for the Wnt5A signaling pathway in cancer drug resistance. Higher cAMP response elements and Tcf/Lef transcription activities were shown in the drug-resistant cancer cells. However, expression of Wnt target genes and CRE activities was downregulated in Wnt5A shRNA stably-transfected MES-SA/Dx5 cells. Cell viability of the drug-resistant cancer cells was also reduced by doxorubicin treatment and Wnt5A shRNA transfection, or by Wnt5A depletion. The in vitro data were supported by immunohistochemical analysis of 24 paired breast cancer biopsies obtained pre- and post-chemotherapeutic treatment. Wnt5A, VEGF and/or ABCB1 were significantly overexpressed after treatment, consistent with clinical chemoresistance. Taken together, the Wnt5A signaling pathway was shown to contribute to regulating the drug-resistance protein ABCB1 and β-catenin-related genes in antagonizing the toxic effects of doxorubicin in the MDR cell lines and in clinical breast cancer samples." @default.
• W1521800058 created "2016-06-24" @default.
• W1521800058 creator A5001390997 @default.
• W1521800058 creator A5009079630 @default.
• W1521800058 creator A5009362862 @default.
• W1521800058 creator A5029437740 @default.
• W1521800058 creator A5030477198 @default.
• W1521800058 creator A5044415219 @default.
• W1521800058 creator A5053732561 @default.
• W1521800058 creator A5076615898 @default.
• W1521800058 creator A5083510599 @default.
• W1521800058 creator A5087489224 @default.
• W1521800058 creator A5091816607 @default.
• W1521800058 date "2014-10-24" @default.
• W1521800058 modified "2023-10-17" @default.
• W1521800058 title "Wnt5A regulates ABCB1 expression in multidrug-resistant cancer cells through activation of the non-canonical PKA/β-catenin pathway" @default.
• W1521800058 cites W1500113837 @default.
• W1521800058 cites W1544740042 @default.
• W1521800058 cites W1593447645 @default.
• W1521800058 cites W1763281581 @default.
• W1521800058 cites W1850622634 @default.
• W1521800058 cites W1963629215 @default.
• W1521800058 cites W1979426842 @default.
• W1521800058 cites W1980565096 @default.
• W1521800058 cites W1981551041 @default.
• W1521800058 cites W1981801066 @default.
• W1521800058 cites W1985176138 @default.
• W1521800058 cites W1986806498 @default.
• W1521800058 cites W1987017438 @default.
• W1521800058 cites W1991958056 @default.
• W1521800058 cites W1994229067 @default.
• W1521800058 cites W1995267211 @default.
• W1521800058 cites W1995404972 @default.
• W1521800058 cites W2004150291 @default.
• W1521800058 cites W2006149509 @default.
• W1521800058 cites W2010885536 @default.
• W1521800058 cites W2013369476 @default.
• W1521800058 cites W2024499742 @default.
• W1521800058 cites W2027328398 @default.
• W1521800058 cites W2031088707 @default.
• W1521800058 cites W2031890346 @default.
• W1521800058 cites W2032167680 @default.
• W1521800058 cites W2043829191 @default.
• W1521800058 cites W2055025559 @default.
• W1521800058 cites W2055904567 @default.
• W1521800058 cites W2059399555 @default.
• W1521800058 cites W2059491046 @default.
• W1521800058 cites W2061773900 @default.
• W1521800058 cites W2063110349 @default.
• W1521800058 cites W2064949970 @default.
• W1521800058 cites W2065692225 @default.
• W1521800058 cites W2065920166 @default.
• W1521800058 cites W2066747012 @default.
• W1521800058 cites W2069262757 @default.
• W1521800058 cites W2071503809 @default.
• W1521800058 cites W2073518184 @default.
• W1521800058 cites W2074966118 @default.
• W1521800058 cites W2077893873 @default.
• W1521800058 cites W2078042264 @default.
• W1521800058 cites W2078701000 @default.
• W1521800058 cites W2088926937 @default.
• W1521800058 cites W2093122635 @default.
• W1521800058 cites W2100584502 @default.
• W1521800058 cites W2100701799 @default.
• W1521800058 cites W2101974243 @default.
• W1521800058 cites W2103163028 @default.
• W1521800058 cites W2105398225 @default.
• W1521800058 cites W2107921995 @default.
• W1521800058 cites W2110257121 @default.
• W1521800058 cites W2116535376 @default.
• W1521800058 cites W2120350646 @default.
• W1521800058 cites W2125916283 @default.
• W1521800058 cites W2143972162 @default.
• W1521800058 cites W2145455405 @default.
• W1521800058 cites W2147257521 @default.
• W1521800058 cites W2147602559 @default.
• W1521800058 cites W2147864074 @default.
• W1521800058 cites W2149077872 @default.
• W1521800058 cites W2154499245 @default.
• W1521800058 cites W2155884637 @default.
• W1521800058 cites W2156088967 @default.
• W1521800058 cites W2158843303 @default.
• W1521800058 cites W2159724914 @default.
• W1521800058 cites W2162606414 @default.
• W1521800058 cites W2170098917 @default.
• W1521800058 cites W2212607974 @default.
• W1521800058 cites W2312709749 @default.
• W1521800058 cites W2323196655 @default.
• W1521800058 cites W84182309 @default.
• W1521800058 doi "https://doi.org/10.18632/oncotarget.2631" @default.
• W1521800058 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4322984" @default.
• W1521800058 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25401518" @default.
• W1521800058 hasPublicationYear "2014" @default.
• W1521800058 type Work @default.
• W1521800058 sameAs 1521800058 @default.
• W1521800058 citedByCount "55" @default.
• W1521800058 countsByYear W15218000582015 @default.
• W1521800058 countsByYear W15218000582016 @default.

• next